Cangene Corp. has been awarded a multiple award indefinite delivery/indefinite quantity contract to potentially provide its Anthrax Immune Globulin Intravenous (AIGIV) to the U.S. Department of Health and Human Services (HHS) for the U.S. government’s biodefense program. Cangene’s AIGIV, a hyperimmune antibody product specific for Bacillus anthracis bacteria, was first accepted into the U.S. Strategic National Stockpile in 2007. Under the terms of the five-year contract, Cangene cou...